Ahmed Glaucoma Valve And Single-Plate Molteno Implants In Treatment Of Refractory Glaucoma: A Comparative Study
Published 2025 - 43rd Congress of the ESCRS
Reference: PO644 | Type: Free paper | DOI: 10.82333/hw1e-7108
Authors: Kourosh Sheibani 1 , Nader Nassiri* 2 , Maryam Yadgari 3 , Soheil Adib-Moghaddam 4 , Sara Kavousnezhad 5
1Ophthalmology,Basir Eye Health Research Center,Tehran,Iran, Islamic Republic Of, 2Ophthalmology,Imam Hossein Medical Center, Shahid Beheshti University of Medical Sciences,Tehran,Iran, Islamic Republic Of, 3Ophthalmology,Imam Hossein Medical Center,Tehran,Iran, Islamic Republic Of, 4Ophthalmology,Universal Council of Ophthalmology (UCO),Tehran,Iran, Islamic Republic Of, 5Ophthalmology,Vanak Eye Surgery Center,Tehran,Iran, Islamic Republic Of
Purpose
To report 2-year follow-up data after Ahmed valve implantation (New World Medical, Inc) and Molteno single-plate implantation surgical treatment of refractory glaucoma.
Setting
Imam Hossein Hospital, Tehran, Iran.
Methods
Patients with refractory glaucoma, defined as uncontrolled intraocular pressure (IOP) of more than 21 mmHg despite maximal antiglaucoma medication, previously failed nonseton surgical treatment, or a combination thereof were included. Ninety-two patients were allocated randomly to each of the study groups and underwent implantation of either the Ahmed valve implant (model FP7; 184 mm2 surface area) or Molteno single-plate implant (134 mm2 surface area) and were followed up for 24 months. Main outcome measures were IOP and surgical success rate. Other outcome measures were changes in visual acuity, number of ant-glaucoma medications, mean deviation of visual field, and rate of intraoperative and postoperative complications.
Results
Those who successfully completed the trial (28 in the Molteno group and 29 in the Ahmed group) achieved significantly less IOP and fewer glaucoma medications, but worse visual acuity 24 months after surgery. The Molteno group, compared with the Ahmed group, achieved significantly lower IOPs after the early postoperative period until the end of the study. Both groups reasonably maintained visual field during the follow-up. The rate of surgical failure was comparable in both groups. Median survival time was 24 months for both groups. There were no devastating intraoperative or postoperative complications in either group.
Conclusions
Both Ahmed and Molteno implants successfully preserved visual field, although IOP control was more pronounced in the Molteno implant group.